Biotech Values

[WID]

IDEV

The company's approved products consist of SANCTURA, a muscarinic receptor antagonist, and SANCTURA XR for the treatment of overactive bladder that are co-promoted with its partner Allergan, Inc.

SANCTURA XR was approved by the U.S. Food and Drug Administration (FDA) on August 3, 2007 and is available on the market in the U.S. as of January 2008. SANCTURA XR is currently being marketed jointly with Allergan, Inc.

Please make your comments, I appreciate your time and knowledge.

Disclosures: I am holding IDIX and MNTA.

Thanks a lot!
WID